Draupnir Bio ApS: Financial statements 2025
CVR: 38546880
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2025. Equity in the 2025 report amounted to DKK 15,256,000. The solvency ratio was 39%. The company had 9 employees in the financial year.
- Equity
- DKK 15,256,000
- Total Assets
- DKK 39,072,000
- Employees
- 9
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | - | - | 15.3 mio. | 9 |
| 2024 | - | - | - | 27.6 mio. | 8 |
| 2023 | - | - | -41.2 mio. | 29.4 mio. | 10 |
| 2022 | - | - | -39.9 mio. | 18.6 mio. | 13 |
| 2021 | - | - | -67 mio. | 53.5 mio. | - |
Official annual report
How creditworthy is Draupnir Bio ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Draupnir Bio ApS has published its annual report for 2024.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The board consists of Eva-Lotta Coulter (chair), Emmanuelle Coutanceau, Ivan Burkov and Robert Andrew Donald Scott. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. According to the 2025 annual report, the company had an average of 9 employees. Equity in the 2025 report amounted to DKK 15,256,000.